Table 4. Cases of relapsed/refractory ALK+ALCL patients treated with ALK inhibitors.
| No. | Author | Reference | Agent | Age/ Sex |
Stage | Previous therapy line | Previous SCT |
SCT
after treatment with crizotinib |
Best response |
Duration of response (month) |
Status at last observation | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gambacorti- Passerini C |
J Natl Cancer Inst. 2014 (#1,2: New Engl J Med. 2011) |
Crizotinib | 26F | IIIB | CHOP, DHAP, HD-VP16 | No | No | CR | >40 | CR, on crizotinib | |||||||||||
| 2 | 20M | IVB | CHOP, DHAP, BEAM | autologous | No | CR | 2 | relapsed, dead | ||||||||||||||
| 3 | 22 | IIB | CHOP, VAD, HyperCVAD/MA | No | No | CR | >35 | CR, on crizotinib | ||||||||||||||
| 4 | 20 | IIB | CHOP, DHAP, BEAM | autologous | No | CR | 2 | relapsed after 2 months, alive in CR on BV | ||||||||||||||
| 5 | 47 | IIIBe | IEV, DHAP, CHOP | No | No | CR | >30 | CR, on crizotinib | ||||||||||||||
| 6 | 28 | IIIB | CHOP, DHAP, mini-BEAM | No | allogeneic | CR | 2 | Crizotinib was used as bridge to SCT. CR with cGVHD |
||||||||||||||
| 7 | 34 | IVBe | CHOP, ESHAP | No | allogeneic | CR | 3 | Crizotinib was used as bridge to SCT and restarted upon
relapse after SCT. It was stopped again 10 months after SCT. CR with cGVHD |
||||||||||||||
| 8 | 38 | IVB | CHOP, DHAP, VIM | allogeneic | No | CR | 8 | Crizotinib was stopped. CR with cGVHD |
||||||||||||||
| 9 | 55 | IIIB | CHOP | No | No | CR | >21 | CR, on crizotinib | ||||||||||||||
| 10-18 | Mossé YP | Lancet Oncol. 2013 | Crizotinib | median 10 |
NR | multiagent chemotherapy | autologous in 1 |
SCT in 3 | CR: 7, PR: 1, SD: 1 |
5 patienes were on crizotinib | ||||||||||||
| 19 | Ordemann R | Ann Hematol. 2013 | Crizotinib | 29M | IVB | CHOP, DHAP, Dexa-BEAM | No | allogeneic | PR? | 1 | relapsed and treated with BV and donor lymphocyte infusion | |||||||||||
| 20 | Cleary JM | J Natl Compr Canc Netw. 2014 | Crizotinib | 34M | IV | CHOP, gemcitabine-based therapy, pralatrexate, high-dose MTX |
No | allogeneic | CR | 3 | Crizotinib was stopped. alive in CR for 30 months |
|||||||||||
| 21 | Conyers R | Eur J Haematol. 2014 | Crizotinib | 22M | IIIB | CHOP, RT | No | allogeneic | CR | >21 | Crizotinib was stopped, but restarted upon relapse after
SCT. CR for >21 months on crizotinib |
|||||||||||
| 22 | Lawrence K | BMC Res Notes. 2015 | Crizotinib | 32M | IV | CHOP, GDP, BV | No | allogeneic | PD | - | died 6 months after SCT | |||||||||||
| 23 | Richly H | Blood. 2015 | Ceritinib | 40M | IV | HyperCVAD | No | NR | CR | >26 | CR, on ceritinib | |||||||||||
| 24 | 48F | IIIB | CHOP | No | NR | CR | >24 | CR, on ceritinib | ||||||||||||||
| 25 | 24M | IIIA | CHOP | No | NR | PR | >20 | PR, on ceritinib | ||||||||||||||
| 26 | Kothari S | J Med Case Rep. 2016 | Crizotinib | 48M | IVB | CHOP, splenectomy, ICE | No | No | CR | >29 | CR, on crizotinib | |||||||||||
| 27 | Mahuad CV | Rare Tumors 2016 | Crizotinib | 16F | IVBe | CHOP, ESHAP | autologous | No | CR | >36 | CR, on crizotinib |
SCT, stem cell transplantation; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; DHAP, dexamethasone, cisplatin, cytarabine; HD-VP16, high-dose etoposide; BEAM, carmustine, etoposide, cytarabine, melphalan; VAD, vincristine, doxorubicin, high-dose dexamethasone; HyperCVAD/MA, alternate regimens of 1) cyclophosphamide, vincristine, doxorubicin, dexamethasone; 2) methotrexate and cytarabine; IEV, Ifosfamide, epirubicin, etoposide; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; VIM, ifosfamide, mitoxantrone, etoposide; Dexa, dexamathasone; RT, radiotherapy; GDP, gemcitabine, dexamethasone, cisplatin; BV, brentuximab vedotin; ICE, ifosfamide, carboplatin, and etoposide; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NR, not reported
cGVHD, graft versus host disease